Journal of Neuro-Oncology

, Volume 141, Issue 1, pp 19–30 | Cite as

MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44

  • Ling Li
  • Mei-Ying Shao
  • Shu-Cheng Zou
  • Zhe-Feng XiaoEmail author
  • Zhu-Chu ChenEmail author
Laboratory Investigation



Glioblastoma (GBM) is the most common malignant tumor originating in the brain parenchyma. The invasive and infiltrative properties of glioblastoma result in poor clinical prognosis to conventional therapies. Emerging reports on microRNAs as important regulators during the process of EMT provide new insights into treating glioblastoma through new targets. However, underlying molecular mechanism of the regulation of miR-101-3p in glioblastoma remains unclear.


Level of miR-101-3p was determined in GBM cell lines by qRT-PCR. MTT, colony formation and transwell assays were utilized to evaluate functions of overexpression of miR-101-3p/knock down of TRIM44 on proliferation, migration and invasion in GBM cells. Direct interaction between miR-101-3p and TRIM44 was validated using dual luciferase reporter system and impacts of overexpression of miR-101-3p/knock down of TRIM44 on regulation of EMT markers were assessed by Western blotting.


MiR-101-3p was validated to be repressed expressed in glioblastoma cancer cell lines. Both overexpression of miR-101-3p and knock down of TRIM44 attenuated proliferation, migration and invasion of glioblastoma cell lines in vitro. TRIM44 was shown to promote EMT in GBM progress and reverse inhibitory function of miR-101-3p. MiR-101-3p was found to suppress the expression of TRIM44 via directly targeting its 3′UTR.


Our findings suggested miR-101-3p regulated proliferation and migration of glioblastoma cells through attenuating TRIM44 induced EMT via direct targeting 3′UTR of TRIM44, which provided preliminary study of potential therapeutic target in future GBM treatment.


Glioblastoma MiR-101-3p TRIM44 EMT 



We would like to give our sincere gratitude to the reviewers for their constructive comments.

Author contributions

LL: Guarantor of integrity of the entire study, LL, SMY: study concepts, XZF, CZC: study design, LL, ZSC: definition of intellectual content, SMY, ZSC: literature research, SMY, XZF: clinical studies, SMY, XZF: experimental studies, CZC: data acquisition, CZC, ZSC: data analysis, XZF, CZC: statistical analysis, XZF, CZC: manuscript preparation, LL, SMY: manuscript editing, LL: manuscript review.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    Buckner JC et al (2007) Central nervous system tumors. Mayo Clin Proc 82(10):1271–1286CrossRefGoogle Scholar
  2. 2.
    Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefGoogle Scholar
  3. 3.
    Quick A et al (2010) Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 5(1):14–27CrossRefGoogle Scholar
  4. 4.
    Iser IC et al (2017) The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation. Med Res Rev 37(2):271–313CrossRefGoogle Scholar
  5. 5.
    Mahabir R et al (2014) Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro Oncol 16(5):671–685CrossRefGoogle Scholar
  6. 6.
    Liao H et al (2015) MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget 6(11):8914–8928Google Scholar
  7. 7.
    Ying Xing QM, Chen X, Zhao Y, Liu W, Jing, Hu, Feng, Xue XW, Cai L (2016) TRIM44 promotes proliferation and metastasis in non-small cell. Oncotarget 7(21):30479–30491Google Scholar
  8. 8.
    Li Q et al (2016) MicroRNA-663 inhibits the proliferation, migration and invasion of glioblastoma cells via targeting TGF-beta1. Oncol Rep 35(2):1125–1134CrossRefGoogle Scholar
  9. 9.
    Chen W et al (2018) Downregulation of miR205 is associated with glioblastoma cell migration, invasion, and the epithelial-mesenchymal transition, by targeting ZEB1 via the Akt/mTOR signaling pathway. Int J Oncol 52(2):485–495Google Scholar
  10. 10.
    Ma C et al (2017) MicroRNA-10b mediates TGF-beta1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition. Int J Oncol 50(5):1739–1748CrossRefGoogle Scholar
  11. 11.
    Yan Y et al (2015) miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. FEBS Lett 589(6):756–765CrossRefGoogle Scholar
  12. 12.
    Smits M et al (2010) miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1(8):710–720Google Scholar
  13. 13.
    Xiaoping L et al (2013) CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in glioma. Cell Death Dis 4:e675CrossRefGoogle Scholar
  14. 14.
    Ma C et al (2016) miR-101 inhibits glioma cell invasion via the downregulation of COX-2. Oncol Lett 12(4):2538–2544CrossRefGoogle Scholar
  15. 15.
    Tian T et al (2016) MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3beta in glioblastoma. Oncotarget 7(48):79584–79595CrossRefGoogle Scholar
  16. 16.
    Liu N et al (2017) MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9. Oncotarget 8(12):19244–19254Google Scholar
  17. 17.
    Hatakeyama S, Family Proteins TRIM (2017) Roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci 42(4):297–311CrossRefGoogle Scholar
  18. 18.
    Hatakeyama S (2011) TRIM proteins and cancer. Nat Rev Cancer 11(11):792–804CrossRefGoogle Scholar
  19. 19.
    Ong CA et al. (2014) Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst. Google Scholar
  20. 20.
    Kawabata H et al. (2017) TRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-kappaB signaling. Int J Mol Sci 18(9):1931CrossRefGoogle Scholar
  21. 21.
    Xing Y et al (2016) TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway. Oncotarget 7(21):30479–30491CrossRefGoogle Scholar
  22. 22.
    Zhou Z et al (2017) Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/beta-catenin signaling pathway. Biomed Pharmacother 96:98–103CrossRefGoogle Scholar
  23. 23.
    Yamada Y et al (2017) A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. Cancer Sci 108(1):32–41CrossRefGoogle Scholar
  24. 24.
    Peng R et al. (2018) Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. Cancer Med 7:796–808Google Scholar
  25. 25.
    Ostrom QT et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1–i63CrossRefGoogle Scholar
  26. 26.
    Gui T, Shen K (2012) miRNA-101: a potential target for tumor therapy. Cancer Epidemiol 36(6):537–540CrossRefGoogle Scholar
  27. 27.
    Zhao S et al (2015) Loss of microRNA-101 promotes epithelial to mesenchymal transition in hepatocytes. J Cell Physiol 230(11):2706–2717CrossRefGoogle Scholar
  28. 28.
    Ye Z et al (2016) Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Oncotarget 7(25):37524–37535Google Scholar
  29. 29.
    Guo F et al (2014) MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep 31(5):2021–2028CrossRefGoogle Scholar
  30. 30.
    Zheng M et al (2015) Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma. Oncotarget 6(9):6797–6810Google Scholar
  31. 31.
    Jiang W et al (2016) miRNA-101 suppresses epithelial-to-mesenchymal transition by targeting HMGA2 in pancreatic cancer cells. Anticancer Agents Med Chem 16(4):432–439CrossRefGoogle Scholar
  32. 32.
    Chandra Mangalhara K et al (2017) ERK2-ZEB1-miR-101-1 axis contributes to epithelial-mesenchymal transition and cell migration in cancer. Cancer Lett 391:59–73CrossRefGoogle Scholar
  33. 33.
    Cui Y et al (2017) Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/beta-catenin signaling pathway. Oncotarget 8(11):17785–17794CrossRefGoogle Scholar
  34. 34.
    Chen W et al (2017) MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway. Oncotarget 8(55):94317–94329Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya HospitalCentral South UniversityChangshaPeople’s Republic of China
  2. 2.Department of NeurosurgeryBrain Hospital of Hunan ProvinceChangshaPeople’s Republic of China

Personalised recommendations